Early FDG-PET response–adapted risk stratification and further therapeutic decision-making in lymphoma: will this replace the established prognostic indices and be the standard-of-care in clinical management?

Letter to the Editor

References

  1. 1.
    Prognostic index for Hodgkin's disease according to Hasenclever. European Society of Medical Oncology. http://www.esmo.org/education/practice-tools/web-based-practice-tools/hasenclever-index-for-hodgkins-disease.html. Accessed September 13, 2009.
  2. 2.
    Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: international prognostic factors project on advanced Hodgkin's disease. N Engl J Med. 1998;339:1506–14.CrossRefPubMedGoogle Scholar
  3. 3.
    Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:22–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376–81.CrossRefPubMedGoogle Scholar
  5. 5.
    Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514–23.CrossRefPubMedGoogle Scholar
  6. 6.
    Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian–Danish study. J Clin Oncol. 2007;25:3746–52.CrossRefPubMedGoogle Scholar
  8. 8.
    Bishu S, Quigley JM, Bishu SR, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma. 2007;48:1548–55.CrossRefPubMedGoogle Scholar
  9. 9.
    Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386–95.CrossRefPubMedGoogle Scholar
  10. 10.
    HD16 for early stage Hodgkin lymphoma. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00736320. Accessed September 13, 2009.
  11. 11.
    Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50(Suppl 1):21S–30S.CrossRefPubMedGoogle Scholar
  12. 12.
    Positron emission tomography (PET)-adapted chemotherapy in advanced Hodgkin lymphoma (HL). ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00795613. Accessed September 13, 2009.
  13. 13.
    Tailoring treatment for B cell non-Hodgkin's lymphoma based on PET scan results mid treatment. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00324467. Accessed September 13, 2009.
  14. 14.
    Positron emission tomography guided therapy of aggressive non-Hodgkin's lymphomas (PETAL). ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00554164. Accessed September 13, 2009.

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Radiation Medicine Centre (BARC)Tata Memorial Hospital AnnexeBombayIndia

Personalised recommendations